Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UBT38006 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| UBT38006 | EXPERIMENTAL | s.c, single dose |
| Placebo | PLACEBO_COMPARATOR | s.c, single dose |
| Insulin Degludec Active Control | ACTIVE_COMPARATOR | 0.4U/kg Insulin Degludec Injection，single subcutaneous injection |
| Insulin Icodec Active Control | ACTIVE_COMPARATOR | 1.25U/kg Insulin icodec Injection，single subcutaneous injection |
| Name | Type | Description |
|---|---|---|
| UBT38006 | DRUG | Ascending single doses - 4 dose levels |
| Placebo | DRUG | Ascending single doses - 4 dose levels |
| Insulin Degludec Injection | DRUG | single subcutaneous injection |
| Insulin Icodec Injection | DRUG | single subcutaneous injection |
Inclusion Criteria: * Aged 18-45 years (inclusive) at the time of informed consent form (ICF) signing; * Sex: Male; * Body weight ≥50.0 kg and body mass index (BMI) between 19.0-24.0 kg/m² (BMI = weight \[kg\] / height² \[m²\]), inclusive, at Screening; * Fasting plasma glucose (FPG) between 3.9-6....
UBT38006 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus (T2DM). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
UBT38006 is being developed by United Therapeutics Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol UTHR.
UBT38006 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved for any use. The ongoing Phase 1 trial is designed to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics.
UBT38006 is being studied in a Phase 1 clinical trial registered as NCT07630233. This randomized, double-blind, placebo-controlled study is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single subcutaneous injection of UBT38006 in healthy adult males.
Yes, the ongoing Phase 1 trial of UBT38006 (NCT07630233) is enrolling healthy adult males aged 18 years and older. The study is placebo-controlled and is being conducted in China, with a planned enrollment of 53 participants.